Bolagspresentation av Diamyd Medicals vd Ulf Hannelius Hannelius, inspelad den 28 augusti 2024 i samband med Aktiespararna digitala temakväll med fokus på Life Science. https://lnkd.in/dPHQrZ9X
Diamyd Medical
Tillverkning av läkemedel
Developing precision medicine therapies for Type 1 Diabetes
Om oss
Diamyd Medical is a Swedish diabetes company developing precision medicine therapies for Type 1 Diabetes. The therapeutic diabetes vaccine Diamyd , an antigen-specific immunotherapy for the preservation of endogenous insulin production, is being evaluated in the ongoing Phase III trial DIAGNODE-3. The company is establishing a vaccine manufacturing facility in Umeå for the manufacture of recombinant GAD65, the active ingredient in the diabetes vaccine. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB. The Diamyd Medical share is traded on Nasdaq First North Growth Market, ticker DMYD B.
- Webbplats
-
https://www.diamyd.com
Extern länk för Diamyd Medical
- Bransch
- Tillverkning av läkemedel
- Företagsstorlek
- 11–50 anställda
- Huvudkontor
- Stockholm
- Typ
- Publikt aktiebolag
- Specialistområden
- Autoimune Diabetes (Type 1 Diabetes and LADA), Pre-clinical and Clinical Development, Development of Combination Therapies for the Treatment of Autoimmune Diabetes, Preserving Beta Cell Function, Pharmaceutical Development och Targeted Immunotherapy
Adresser
-
Primär
Kungsgatan 29
Stockholm, SE-111 56, SE
Anställda på Diamyd Medical
-
Ulf Hannelius
President & CEO @ Diamyd Medical
-
Robert Harris
Professor of NeuroImmunotherapy l Dean of Doctoral Education l Empowering professional leadership and shaping PhD education l Have trained 8000+ PhD…
-
Ginger Vieira
Diabetes Marketing Content Specialist | Writer & Editor | Social Media Content Strategist & Creator
-
Martin Linhult
CMC lead
Uppdateringar
-
Diamyd Medical omdelade detta
The 60th Annual Meeting of the European Association for the Study of Diabetes e.V. (EASD) is fast approaching and the Diamyd Medical team will have a packed schedule to showcase the progress achieved in the last few months: ☑ FDA Fast-Track designation for treatment of stage 1-3 Type1 Diabetes ☑ Progress in the recognition of c-peptide as an approvable endpoint ☑ Positive interim analysis of the Phase 3 trial DIAGNODE-3 Highlights: 9th of September ⏩ Christoph Nowak, MD, PhD will deliver a company presentation at the INNODIA Symposium, organized by Manuela Battaglia and her team (register here ➡ https://lnkd.in/eZWnZDkm). 11th of September ⏩ Ulf Hannelius will deliver an oral presentation - SO 009 Treatment of type 1 diabetes "Exploring HLA genotype variations in type 1 diabetes: implications for precision medicine and immunotherapy response" my colleagues Linnea Eriksson, Martina Widman and Anton Lindqvist will be @ Booth E.16 #EASD2024
-
-
Diamyd Medical omdelade detta
Diamyd Medical - Viktiga nyheter väntar mot slutet av året Se intervjun här: https://lnkd.in/dWR2VA9D I en intervju berättar Ulf Hannelius, VD på Diamyd Medical, om vad som hänt i bolaget under sommaren. $DMYD.B
Diamyd Medical - Uppdatering kring sommarens händelser
https://www.youtube.com/
-
Diamyd Medicals vd Ulf Hannelius i #Penserpodden med » Alexander Gustafsson och analytiker Ludvig Svensson 📻
#Penserpodden Avsnitt 299: Life science podd med Dicot & Diamyd Det är 26 år sedan potensläkemedlet Viagra gavs ut och inga nya större läkemedel har nått den marknaden sen dess. Elin Trampe är VD på Dicot Pharma AB Pharma och deras läkemedelskandidat LIB-01 adresserar just erektionssvikt. Potentialen i deras molekyl får vi höra mer om i avsnittet. Vi följer också upp med Ulf Hannelius, VD på Diamyd Medical om deras väldigt intensiva sommar. Fast Track från FDA i USA, positiv interimanalys under början av augusti och vad nästa steg är berättar Ulf om i podden. Lyssna in! Lyssna in här: Spotify: https://lnkd.in/dGx97rg7 SoundCloud: https://lnkd.in/dkSK4kMs
-
-
Diamyd Medical omdelade detta
Last Friday the SARQA board was gathered for a F2F meeting in Umeå. We got an introduction by Peter Jacobsson on the functions of, and activities at, Umeå Biotech Incubator, held our meeting for planning future SARQA-events – primarily the autumn meeting on October 17th – look out for the agenda! On our way to lunch we visited Diamyd Medical where Maja Johansson informed on the progress of the Drug Substance manufacturing facility. After lunch a walk and talk meet on future SARQA priorities at the Skulpturparken (https://lnkd.in/db5E5vcq) before getting back for final discussions. A really productive day and nice to be able to show a piece of Umeå at the same time! / Maria Åhman
Styrelsen samlad i Umeå I fredags var hela SARQAs styrelse samlad i Umeå för ett heldags styrelsemöte på Umeå BioTech Incubator. Vi hann även med ett intressant besök på Diamyd Medical där ledamot Maria Åhman jobbar. En stor del av dagen gick åt att planera vårt spännande och intressanta höstmöte den 17:e oktober i Stockholm. Vi hoppas vi ses där!
-
-
”Läkemedelsbolaget Diamyd Medical, som utvecklar banbrytande behandlingar för typ 1-diabetes, har levererat en rad tunga nyheter på kort tid. Nyligen presenterades mycket positiva resultat från en viktig interimsanalys. Dessutom har bolagets läkemedel fått snabbspårstatus ”Fast Track designation” av den amerikanska läkemedelsmyndigheten FDA, vilket kan påskynda marknadslanseringen". Läs artikeln här https://lnkd.in/dMksyHF5
-
"A positive readout of the interim data was critical for the case and comes as much appreciated news." - download the full commissioned report by Penser Access analyst Ludvig Svensson at https://lnkd.in/duyU9zfx
-
“We are extremely pleased with the DSMB's recommendation to continue the DIAGNODE-3 trial as planned,” says Ulf Hannelius, CEO of Diamyd Medical. Diamyd Medical announces positive interim analysis results for Phase 3 Trial in Type 1 Diabetes. Full press release here: https://lnkd.in/dVyAZGfc
🚀 Very important milestone for Diamyd® and our phase 3 trial in #T1D! 🚀 I am very happy to share that Diamyd Medical has achieved a significant milestone in our Phase 3 #DIAGNODE-3 trial for Type 1 Diabetes. The independent Data Safety Monitoring Board has reviewed the interim analysis and given us the green light to continue without any modifications. This positive outcome, together with the recent positive news around fast track designation for stages 1, 2 and 3 T1D for the antigen-specific immunotherapy Diamyd® as well as the positive interaction with the US FDA around C-peptide as a surrogate marker and potential for accelerated approval, marks crucial steps towards our goal of providing a potentially groundbreaking therapy for those affected by Type 1 Diabetes. We are dedicated to advancing Diamyd® through the accelerated approval pathway and we look forward to achieving our next milestones towards this goal. Thank you again to the whole team and our partners, clinics, patients and shareholders for your unwavering support! 💙💙 Read the press release here: https://lnkd.in/dmuCqtZJ #DiabetesResearch #PrecisionMedicine #ClinicalTrials #DiamydMedical #Type1Diabetes #immunotherapy Breakthrough T1D Sanjoy Dutta Joshua Vieth Olivia Lou, Ph.D. Mark Atkinson Johnny Ludvigsson Erik Nerpin Anders Essen-Möller Maria-Teresa Essen-Möller Torbjörn Bäckström, MD., Ph.D. Karin Hehenberger Karin Rosen MD PhD Martina Widman Anton Lindqvist Christoph Nowak, MD, PhD Maja Johansson Anna Styrud Linnea Eriksson Pedro F. Teixeira, PhD
Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes
diamyd.com
-
Diamyd Medical omdelade detta
The US FDA has agreed to fast track a vaccine designed to prevent type 1 diabetes! -- This isn’t approval, but it’s a big step forward for Diamyd. That’s the name of the medication and the company, Diamyd Medical. On the podcast this week, we’ll talk about their clinical trials. Elna Narula explains, they’re recruiting right now. -- Listen at https://lnkd.in/dwfRzFB or wherever you get podcasts. -- Diamyd Medical’s approach involves using a specific protein, GAD65, to teach the immune system not to attack the pancreas. You'll hear who they need for their trials, how to see if you’re eligible, and where the trials will take place. -- #DiabetesConnections #Diamyd #T1D
-
-
Diamyd Medical omdelade detta
I am thrilled to announce that Diamyd Medical has received positive feedback from the FDA regarding an Accelerated Approval pathway for our #precisionmedicine #immunotherapy, Diamyd®, designed to treat patients with Stage 3 Type 1 Diabetes carrying the HLA DR3-DQ2 genotype. In a recent meeting, the #FDA acknowledged that #Cpeptide could be used as a surrogate endpoint reasonably likely to predict the clinical benefit of preservation of endogenous insulin production. ➡️This is very important and means that #AcceleratedApproval could be sought based on a demonstration of significant treatment-related benefits on C-peptide levels in response to Diamyd® administration. For the full press release see: https://lnkd.in/dvAzhp8C Thank you to our super team, partners, and the FDA for their continued support. Together, we are making strides towards a future where #t1d can be better managed, treated and eventually prevented ❤️ Breakthrough T1D Johnny Ludvigsson Mark Atkinson Anders Essen-Möller Karin Hehenberger Karin Rosen MD PhD Torbjörn Bäckström, MD., Ph.D. Maria-Teresa Essen-Möller Erik Nerpin Martina Widman Maja Johansson Anna Styrud Pedro F. Teixeira, PhD Eva Karlström Kerstin Malm Pontus Rådén Elna Narula
-
Liknande sidor
Finansiering
Senaste finansieringsrunda
Aktiekapital efter börsintroduktion5 192 567,00 US$